# Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

> **NCT01016366** · PHASE2 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 36 (actual)

## Conditions studied

- Friedreich's Ataxia

## Interventions

- **DRUG:** Lu AA24493
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01016366
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016366, "Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01016366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*